Steven Cohen’s Aspire Biopharma ASBP Stock Holding History

Steven Cohen’s Portfolio ASBP Stock Details ASBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-12	Closed	-$1.88K	–	4679
2025 Q4	$1.88K	Buy	+12	New	+$3K	﹤0.01%	3859

Other funds holding ASBP

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Crewe Advisors Salt Lake City, Utah $1.38B AUM 41.76% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Crossingbridge Advisors Pleasantville, New York $567M AUM 0.34% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Steven Cohen's ASBP Position: Q1 2026 in Review

Steven Cohen sold out of Aspire Biopharma (ASBP) in Q1 2026, closing a stake of 12 shares — an estimated $1.88K sold.

Steven Cohen first reported a position in ASBP in Q4 2025 and held it in 1 quarter. The position peaked at $1.88K in Q4 2025. 12 funds tracked by Wall St. Rank hold ASBP as of Q1 2026.

Steven Cohen reported no remaining Aspire Biopharma position as of Q1 2026 after selling out during the quarter.
Steven Cohen sold 12 Aspire Biopharma shares in Q1 2026, an estimated $1.88K.
Steven Cohen first reported a position in Aspire Biopharma in Q4 2025 and held it in 1 quarter.
Steven Cohen's Aspire Biopharma position peaked at $1.88K in Q4 2025.
12 funds tracked by Wall St. Rank held Aspire Biopharma as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.